Adamas Pharmaceuticals, Inc. Publishes New Data Analyses Demonstrating Gocovri Treatment More Than Doubled on Time without Dyskinesia in Patients with Parkinson’s Disease
March 29, 2021 at 06:45 pm IST
Adamas Pharmaceuticals, Inc. announced the publication of an article entitled “Amantadine ER (Gocovri®) significantly increases ON time without any dyskinesia: Pooled analyses from pivotal studies in Parkinson’s disease”in the peer-reviewed journal Frontiers in Neurology. GOCOVRI® (amantadine) extended release capsules is the first and only medicine approved as a treatment both for dyskinesia in patients with Parkinson’s disease (PD) receiving levodopa-based therapy and as an adjunctive treatment to levodopa/carbidopa in patients with PD experiencing OFF episodes.